Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

20171,015 citationsJournal Articlebronze Open Access

Authors

Parameswaran Nair · St. Joseph’s Healthcare Hamilton

Sally E. Wenzel · University of Pittsburgh

Klaus F. Rabe · LungenClinic Grosshansdorf

Arnaud Bourdin · Centre Hospitalier Universitaire de Montpellier

Njira Lugogo · Duke Medical Center

Piotr Kuna · Medical University of Lodz

Peter Barker

Abstract

Benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. These effects occurred without a sustained effect on the FEV<sub>1</sub>. (Funded by AstraZeneca; ZONDA ClinicalTrials.gov number, NCT02075255 .).

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research IL-33, ST2, and ILC Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 376, Issue 25, pp. 2448-2458

DOI: 10.1056/nejmoa1703501

Field-Weighted Citation Impact: 64.55